Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Myeloid 1Classical hematology 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Magnetic Resonance Spectroscopy 106Specimen Handling 87pembrolizumab 81enzalutamide 64Nivolumab 62Gemcitabine 59Docetaxel 51Abiraterone Acetate 44apalutamide 43Radiosurgery 43Androgen Antagonists 43Prednisone 42darolutamide 40Cisplatin 38Biopsy 36Radiotherapy 34cabozantinib 32Carboplatin 30abiraterone 29Pluvicto 29Ipilimumab 29durvalumab 25Leuprolide 24enfortumab vedotin 23X-Rays 23Radiation 23olaparib 20atezolizumab 20Standard of Care 20avelumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Clinical Trials, Phase I as Topic × Genitourinary × 90 days × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡